Enzo Biochem Statistics
Total Valuation
Enzo Biochem has a market cap or net worth of 28.29 million. The enterprise value is -5.40 million.
| Market Cap | 28.29M |
| Enterprise Value | -5.40M |
Important Dates
The last earnings date was Friday, June 13, 2025.
| Earnings Date | Jun 13, 2025 |
| Ex-Dividend Date | Nov 15, 2024 |
Share Statistics
Enzo Biochem has 52.40 million shares outstanding. The number of shares has increased by 3.46% in one year.
| Current Share Class | 52.40M |
| Shares Outstanding | 52.40M |
| Shares Change (YoY) | +3.46% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 20.26% |
| Owned by Institutions (%) | 21.32% |
| Float | 36.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.03 |
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.26 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.33 |
Financial Position
The company has a current ratio of 2.84, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.84 |
| Quick Ratio | 2.41 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.18 |
| Interest Coverage | -57.26 |
Financial Efficiency
Return on equity (ROE) is -13.95% and return on invested capital (ROIC) is -11.49%.
| Return on Equity (ROE) | -13.95% |
| Return on Assets (ROA) | -8.98% |
| Return on Invested Capital (ROIC) | -11.49% |
| Return on Capital Employed (ROCE) | -24.26% |
| Revenue Per Employee | 209,725 |
| Profits Per Employee | -160,931 |
| Employee Count | 136 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 2.41 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.03% in the last 52 weeks. The beta is 1.14, so Enzo Biochem's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | -38.03% |
| 50-Day Moving Average | 0.54 |
| 200-Day Moving Average | 0.74 |
| Relative Strength Index (RSI) | 70.10 |
| Average Volume (20 Days) | 896,980 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.49 |
Income Statement
In the last 12 months, Enzo Biochem had revenue of 27.47 million and -21.08 million in losses. Loss per share was -0.40.
| Revenue | 27.47M |
| Gross Profit | 11.77M |
| Operating Income | -11.28M |
| Pretax Income | -7.84M |
| Net Income | -21.08M |
| EBITDA | -9.93M |
| EBIT | -11.28M |
| Loss Per Share | -0.40 |
Balance Sheet
The company has 36.69 million in cash and 3.00 million in debt, giving a net cash position of 33.69 million or 0.64 per share.
| Cash & Cash Equivalents | 36.69M |
| Total Debt | 3.00M |
| Net Cash | 33.69M |
| Net Cash Per Share | 0.64 |
| Equity (Book Value) | 43.40M |
| Book Value Per Share | 0.83 |
| Working Capital | 31.27M |
Cash Flow
In the last 12 months, operating cash flow was -15.32 million and capital expenditures -1.03 million, giving a free cash flow of -16.35 million.
| Operating Cash Flow | -15.32M |
| Capital Expenditures | -1.03M |
| Free Cash Flow | -16.35M |
| FCF Per Share | -0.31 |
Margins
Gross margin is 42.83%, with operating and profit margins of -41.06% and -76.73%.
| Gross Margin | 42.83% |
| Operating Margin | -41.06% |
| Pretax Margin | -28.54% |
| Profit Margin | -76.73% |
| EBITDA Margin | -36.13% |
| EBIT Margin | -41.06% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.10, which amounts to a dividend yield of 18.52%.
| Dividend Per Share | 0.10 |
| Dividend Yield | 18.52% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -3.46% |
| Shareholder Yield | 11.35% |
| Earnings Yield | -74.52% |
| FCF Yield | -57.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 21, 2004. It was a forward split with a ratio of 1.05.
| Last Split Date | Oct 21, 2004 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Enzo Biochem has an Altman Z-Score of -4.84 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.84 |
| Piotroski F-Score | 2 |